In Silico Design and Characterization of a Multi-Epitope Vaccine Candidate Against Mycoplasma pneumoniae Using a Reverse Vaccinology Strategy
Open Access
- 2 March 2026
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 567
Abstract
Mycoplasma pneumoniae (M. pneumoniae) is the crucial factor of global acquired respiratory infections. Currently, there are no specific disease modification treatments or vaccines available, and the vaccine development for this pathogen lags behind due to the complexity and variability of its antigens. A novel vaccine with broad-spectrum characteristics is essential to provide comprehensive protection against continuously evolving wild-type strains. Here, a broad-spectrum muti-epitope vaccine against M. pneumoniae had been designed through immunoinformatics methods. To ensure its broad-spectrum, we generated consistent sequences from all the antigen proteins of different strains, and then identified potential T cell epitopes. The multi-epitope vaccine (MEV) of M. pneumoniae incorporated 16 CTLs and 7 HTLs from the HMW1–3 and p1 adhesin proteins, which comprised 458 amino acids with adjuvant. The vaccine evaluation showed that the MEV had ideal physicochemical properties, high antigenicity, high immunogenicity, and was non-toxic. Furthermore, there was a strong and stable binding interaction between this vaccine and the toll-like receptors, which could be supported by the normal mode analysis. Finally, codon optimization resulted in the optimal GC content and higher CAI value. The vaccine candidate is expected to induce strong cellular immune responses and may provide protective immunity against the pathogen. We provided a novel in silico vaccine design strategy for vaccine design, which could provide a technical framework for the development of vaccines against other pathogens.Keywords
Funding Information
- Youth Fund of the Natural Science Foundation of Tianjin (24JCQNJC00460)
This publication has 42 references indexed in Scilit:
- Designing a T cell multi-epitope vaccine against hRSV with reverse vaccinology: An immunoinformatics approachColloids and Surfaces B: Biointerfaces, 2025
- Risk factors for pneumonia among children with coinfection of influenza A virus and Mycoplasma pneumoniaeEuropean Journal of Clinical Microbiology & Infectious Diseases, 2024
- Current Mycoplasma pneumoniae epidemic among children in Shanghai: unusual pneumonia caused by usual pathogenWorld Journal of Pediatrics, 2024
- Insight into the Pathogenic Mechanism of Mycoplasma pneumoniaeCurrent Microbiology, 2022
- An immunoinformatics-based designed multi-epitope candidate vaccine (mpme-VAC/STV-1) against Mycoplasma pneumoniaeComputers in Biology and Medicine, 2022
- Engineering a multi-epitope vaccine candidate against Leishmania infantum using comprehensive Immunoinformatics methodsBiologia, 2021
- Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicityCancer Immunology, Immunotherapy, 2016
- Designing of Complex Multi-epitope Peptide Vaccine Based on Omps of Klebsiella pneumoniae: An In Silico ApproachInternational Journal of Peptide Research and Therapeutics, 2015
- Structure-based functional inference of hypothetical proteins from Mycoplasma hyopneumoniaeJournal of Molecular Modeling, 2011
- An introduction to epitope prediction methods and softwareReviews in Medical Virology, 2008